# Neuromodulation of Inflammation and Endothelial Function

Study · id `cardio:ct-nct05230732` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05230732](<https://clinicaltrials.gov/study/NCT05230732>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05230732

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 158 participants.

## Technical summary

Registry record NCT05230732. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2027-02-27 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 158 participants (planned count; ClinicalTrials.gov record NCT05230732, source copy `cardio:ctgov-nct05230732-2026-08-11`, retrieved 2026-10-26)
- Started: 2022-09-01 (actual) (ClinicalTrials.gov record NCT05230732, source copy `cardio:ctgov-nct05230732-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2027-02-27 (anticipated) (ClinicalTrials.gov record NCT05230732, source copy `cardio:ctgov-nct05230732-2026-08-11`, retrieved 2026-10-26)
- Completion: 2027-02-27 (anticipated) (ClinicalTrials.gov record NCT05230732, source copy `cardio:ctgov-nct05230732-2026-08-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05230732, source copy `cardio:ctgov-nct05230732-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05230732-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Neuromodulation of Inflammation and Endothelial Function
- Condition: Systolic Heart Failure
- Intervention (Device): neuromodulation device
- Intervention (Device): SHAM
- Lead sponsor: University of Oklahoma
- Lead sponsor class: OTHER
- Collaborator: National Institute on Aging (NIA)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: University of Oklahoma (`cardio:org-university-of-oklahoma`)
- Registry lists this organization as a collaborator: National Institute on Aging (`cardio:nia`)

## Provenance

Content hash: 01368ba3b4a65701326709fee3975d707b752d86f39b90ceea5ccfcd245845ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
